On the 12th, Samsung Bioepis announced that it had passed this resolution at a board meeting held the previous day. SAMSUNG EPIS HOLDINGS owns 100% of Samsung Bioepis. The ex-dividend date is the 4th of next month, and the dividend is scheduled to be paid on the 18th of the same month.
A Samsung Bioepis official stated, “This dividend is a routine capital distribution procedure based on Samsung Bioepis’s profit generation,” adding, “It was carried out in accordance with the Commercial Act and our articles of incorporation.”
The spokesperson added, “SAMSUNG EPIS HOLDINGS is reviewing various ways to utilize these funds to ensure stable business operations under the holding company structure and to secure future growth engines in the new drug and biosimilar sectors.”
The policy of utilizing dividends from subsidiaries as a major source of funds for SAMSUNG EPIS HOLDINGS was disclosed last May when the corporate spin-off was announced.
